PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Bannon’s War Room | Morning Edition Hour 2 | Recorded March 1, 2021 | Video: 48 Minutes 55 Seconds

Show Me

March 1, 2020 | Nightly News Rebroadcast | Video: 51 Minutes 25 Seconds

Show Me

New Chauffeur-Hailing Service Seeks to Challenge Uber, Lyft

Show Me

Bannon’s War Room | Saturday Edition Hour 1 | Recorded February 27, 2021 | Video: 48 Minutes 55 Seconds

Show Me

Bannon’s War Room | Saturday Edition Hour 2 | Recorded February 27, 2021 | Video: 48 Minutes 53 Seconds

Show Me

February 26, 2020 | Nightly News Rebroadcast | Video: 51 Minutes 49 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 26, 2021 | Video: 48 Minutes 22 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 26, 2021 | Video: 48 Minutes 41 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded February 26, 2021 | Video: 48 Minutes 59 Seconds

Show Me

February 25, 2020 | Nightly News Rebroadcast | Video: 48 Minutes 17 Seconds

Show Me

VIDEO: Trending as a Transphobe and Bi-Phobe

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 25, 2021 | Video: 48 Minutes 42 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 25, 2021 | Video: 48 Minutes 48 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded February 25, 2021 | Video: 48 Minutes 59 Seconds

Show Me

The Nation Speaks (Feb. 20): Can America Win Space?; Black History Month in 2021; US Critical Thinking Crisis

Show Me

February 24, 2020 | Nightly News Rebroadcast | Video: 43 Minutes 53 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 24, 2021 | Video: 48 Minutes 42 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 24, 2021 | Video: 48 Minutes 36 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded February 24, 2021 | Video: 48 Minutes 36 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 23, 2021 | Video: 48 Minutes 59 Seconds

Show Me

House Democrats, Targeting Right-Wing Cable Outlets, Are Assaulting Core Press Freedoms

Show Me

February 23, 2020 | Nightly News Rebroadcast | Video: 49 Minutes 26 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 23, 2021 | Video: 48 Minutes 38 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded February 23, 2021 | Video: 48 Minutes 59 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 22, 2021 | Video: 48 Minutes 41 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 22, 2021 | Video: 48 Minutes 41 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded February 22, 2021 | Video: 48 Minutes 59 Seconds

Show Me

February 22, 2020 | Nightly News Rebroadcast | Video: 49 Minutes 26 Seconds

Show Me

Donald Trump Full Interview | Banned By Youtube | Recorded February 17, 2021 | Video: 22 Minutes 09 Seconds

Show Me

Congress Escalates Pressure on Tech Giants to Censor More, Threatening the First Amendment

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 19, 2021 | Video: 48 Minutes 46 Seconds

Show Me

February 19, 2020 | Nightly News Rebroadcast | Video: 49 Minutes 53 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 19, 2021 | Video: 48 Minutes 46 Seconds

Show Me

February 18, 2020 | Nightly News Rebroadcast | Video: 49 Minutes 10 Seconds

Show Me

February 17, 2020 | Nightly News Rebroadcast | Video: 52 Minutes 21 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 18, 2021 | Video: 48 Minutes 43 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 18, 2021 | Video: 48 Minutes 50 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded February 18, 2021 | Video: 48 Minutes 58 Seconds

Show Me

February 16, 2020 | Nightly News Rebroadcast | Video: 51 Minutes 53 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 17, 2021 | Video: 48 Minutes 41 Seconds

Show Me